Glenmark Pharmaceuticals Recalls 1,200 Bottles Of Hypertension Drug In US

New Delhi : Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).

The New Jersey-based arm of the drug firm is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride extended-release tablets, Batch # 19224744 as per the latest Enforcement Report of the US health regulator.

The affected lot has been manufactured at the Goa plant of the Mumbai-based drug firm and then supplied to Glenmark Pharmaceuticals Inc, USA, the USFDA said.

The firm is recalling the affected bottles due to it being “Subpotent”, it noted.

Subpotent means ‘Out of Specification for Assay Test at the 3-month time point.’

Glenmark Pharmaceuticals Inc initiated the nationwide (US) Class III recall on August 14 this year, it added.

As per the USFDA, a Class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Related Posts

  • Pharma
  • August 1, 2025
  • 46 views
Trump pressures 17 pharma CEOs to cut US drug prices

WASHINGTON, July 31 (Reuters) – President Donald Trump sent letters to the leaders of 17 major pharmaceutical companies outlining how they should slash U.S. prescription drug prices to match those paid overseas,…

  • Pharma
  • August 1, 2025
  • 57 views
Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

The headline equity benchmarks ended with significant losses today, as investors turned cautious following the U.S. imposition of steep tariffs on multiple trade partners and the reaffirmation of a 25%…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Trump pressures 17 pharma CEOs to cut US drug prices

Trump pressures 17 pharma CEOs to cut US drug prices

Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

Nifty settles below 24,600 level; broader mkt underperforms; pharma shares tumble

Karnataka issues order to merge Ayush drug dept with State FDA

Karnataka issues order to merge Ayush drug dept with State FDA

Orchid Pharma buyback rights to novel antibiotic; stock up 5%

Orchid Pharma buyback rights to novel antibiotic; stock up 5%